Lantan

Lanthanum, the active ingredient in Lantan, is a phosphate binder presented as an oral tablet for oral use. It binds dietary phosphate in the gastrointestinal tract, helping to lower serum phosphate levels in patients with chronic kidney disease who have hyperphosphatemia.

GNH USA supplies Lantan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Lantan (lanthanum) is employed as a phosphate binder to manage elevated serum phosphate in chronic kidney disease. - Hyperphosphatemia in chronic kidney disease: reduces intestinal phosphate absorption to lower serum phosphate levels. - Patients on dialysis: helps achieve target phosphate concentrations recommended by nephrology guidelines. - Secondary hyperparathyroidism management: assists in controlling phosphate load, which indirectly supports PTH regulation.

Lantan may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate discomfort in the stomach. - Constipation: reduced bowel movements, sometimes requiring dietary adjustment. - Abdominal pain: cramping or discomfort in the abdomen. - Diarrhea: loose stools, often transient. - Flatulence: increased gas production. - Vomiting: occasional expulsion of stomach contents.

Serious or Rare Side Effects: - Severe hypophosphatemia: excessively low serum phosphate requiring medical attention. - Intestinal obstruction: blockage of the gastrointestinal tract. - Allergic reactions: rash, itching, or swelling that may indicate hypersensitivity. - Liver enzyme elevation: abnormal liver function tests observed in rare cases.

When prescribing Lantan, clinicians should consider several safety measures. - Monitor serum phosphate: regular blood tests to ensure levels remain within target range. - Assess calcium status: avoid concurrent high calcium intake that could lead to hypercalcemia. - Evaluate bowel health: contraindicated in patients with known bowel obstruction or severe constipation. - Adjust for other binders: coordinate dosing when other phosphate binders are used to prevent over‑binding. - Review concomitant medications: antacids or iron supplements may reduce efficacy and should be spaced appropriately. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lantan can interact with several medicines, affecting its phosphate‑binding capacity.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: may bind lanthanum and reduce its effectiveness. - Iron supplements: can form insoluble complexes, decreasing absorption of both agents. - Tetracycline antibiotics: binding may impair antibiotic absorption.

Moderate Interactions (Monitor Closely): - Calcium carbonate: concurrent use may increase total phosphate binding, requiring dose adjustment. - Sevelamer: combined use may lead to excessive phosphate reduction. - Vitamin D analogues: monitor calcium and phosphate levels to avoid imbalance.